{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:11:37Z","timestamp":1790187097363,"version":"4.1.0"},"reference-count":226,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Allergic conjunctivitis (AC) is a common condition resulting from exposure to allergens such as pollen, animal dander, or mold. It is typically mediated by allergen-induced crosslinking of immunoglobulin E attached to receptors on primed conjunctival mast cells, which results in mast cell degranulation and histamine release, as well as the release of lipid mediators, cytokines, and chemokines. The clinical result is conjunctival hyperemia, tearing, intense itching, and chemosis. Refractory and chronic cases can result in ocular surface complications that may be vision threatening. Patients who experience even mild forms of this disease report an impact on their quality of life. Current treatment options range from non-pharmacologic therapies to ocular and systemic options. However, to adequately control AC, the use of multiple agents is often required. As such, a precise understanding of the immune mechanisms responsible for this ocular surface inflammation is needed to support ongoing research for potential therapeutic targets such as chemokine receptors, cytokine receptors, non-receptor tyrosine kinases, and integrins. This review utilized several published articles regarding the current therapeutic options to treat AC, as well as the pathological and immune mechanisms relevant to AC. This review will also focus on cellular and molecular targets in AC, with particular emphasis on potential therapeutic agents that can attenuate the pathology and immune mechanisms driven by cells, receptors, and molecules that participate in the immunopathogenesis and immunopathology of AC.<\/jats:p>","DOI":"10.3390\/ph15050547","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T22:20:06Z","timestamp":1651184406000},"page":"547","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Therapeutic Targets in Allergic Conjunctivitis"],"prefix":"10.3390","volume":"15","author":[{"given":"Bisant A.","family":"Labib","sequence":"first","affiliation":[{"name":"Pennsylvania College of Optometry, Salus University, Elkins Park, PA 19027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DeGaulle I.","family":"Chigbu","sequence":"additional","affiliation":[{"name":"Pennsylvania College of Optometry, Salus University, Elkins Park, PA 19027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"ref_1","unstructured":"Jain, P., and Ndhlovu, L.C. (2020). Immune mechanisms, pathology, and management of allergic ocular diseases. Advanced Concepts in Human Immunology: Prospects for Disease Control, Springer Nature."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clae.2008.07.003","article-title":"The pathophysiology of ocular allergy: A review","volume":"32","author":"Chigbu","year":"2009","journal-title":"Cont. Lens. Anterior Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1755-3768.2011.02272.x","article-title":"Management of seasonal allergic conjunctivitis: Guide to therapy","volume":"90","author":"Bielory","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/ACI.0b013e32834a9676","article-title":"Epidemiology of allergic conjunctivitis","volume":"11","author":"Rosario","year":"2011","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/187221309788489733","article-title":"Seasonal and perennial allergic conjunctivitis","volume":"3","author":"Wong","year":"2009","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1872213X08666140704113452","article-title":"Seasonal and perennial allergic conjunctivitis","volume":"8","author":"Wong","year":"2014","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3109\/02713683.2013.794248","article-title":"Specific IgE in tear fluid and features of allergic conjunctivitis","volume":"38","author":"Mimura","year":"2013","journal-title":"Curr. Eye Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/OPTH.S63790","article-title":"Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis","volume":"9","author":"Chigbu","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/all.13334","article-title":"Clinical implications of mast cell involvement in allergic conjunctivitis","volume":"73","author":"Rambasek","year":"2018","journal-title":"Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1824-7288-39-18","article-title":"Allergic conjunctivitis: A comprehensive review of the literature","volume":"39","author":"Lionetti","year":"2013","journal-title":"Ital. J. Pediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4274\/tjo.galenos.2020.11456","article-title":"Current Knowledge in Allergic Conjunctivitis","volume":"51","author":"Villegas","year":"2021","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/03946320110240S409","article-title":"Gene-environment interaction in childhood asthma","volume":"24","author":"Rigoli","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0091-6749(87)80010-6","article-title":"Longitudinal changes in allergen skin test reactivity in a community population sample","volume":"79","author":"Barbee","year":"1987","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1034\/j.1398-9995.2003.00161.x","article-title":"Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Munster, Germany","volume":"58","author":"Maziak","year":"2003","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1067\/mai.2003.1484","article-title":"Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study","volume":"111","author":"Verlato","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1542-0124(12)70297-5","article-title":"Immunoregulation on the ocular surface: 2nd Cullen Symposium","volume":"7","author":"Pflugfelder","year":"2009","journal-title":"Ocul. Surf."},{"key":"ref_17","first-page":"4093","article-title":"Corneal epithelial tight junctions and their response to lipopolysaccharide challenge","volume":"41","author":"Yi","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1167\/iovs.08-2606","article-title":"Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells","volume":"50","author":"Kimura","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"C1213","DOI":"10.1152\/ajpcell.00558.2003","article-title":"The tight junction: A multifunctional complex","volume":"286","author":"Schneeberger","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4419-8056-4_5","article-title":"The Role of Histamine in Ocular Allergy","volume":"709","author":"Ohbayashi","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.0105-2896.2009.00873.x","article-title":"Dendritic cell physiology and function in the eye","volume":"234","author":"Forrester","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11882-003-0098-2","article-title":"Epithelial cells in ocular allergy","volume":"3","author":"Bozkurt","year":"2003","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_23","first-page":"S180","article-title":"Influence of the eye-associated lymphoid tissue (EALT) on inflammatory ocular surface disease","volume":"3","author":"Knop","year":"2005","journal-title":"Ocul. Surf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000099252","article-title":"Anatomy and immunology of the ocular surface","volume":"92","author":"Knop","year":"2007","journal-title":"Chem. Immunol. Allergy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1469-7580.2005.00394.x","article-title":"The role of eye-associated lymphoid tissue in corneal immune protection","volume":"206","author":"Knop","year":"2005","journal-title":"J. Anat."},{"key":"ref_26","first-page":"1270","article-title":"Conjunctiva-associated lymphoid tissue in the human eye","volume":"41","author":"Knop","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_27","unstructured":"Dartt, D.A.D.R., D\u2019Amore, P., and Niederkorn, J.Y. (2011). Adaptive immune system and the eye: T cell-mediated immunity. Immunology, Inflammation and Diseases of the Eye, Academic Press."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.all.0000182545.75842.77","article-title":"The role of the conjunctival epithelium in ocular allergy","volume":"5","author":"Calonge","year":"2005","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/exer.1998.0528","article-title":"The role of conjunctival epithelial cells in chronic ocular allergic disease","volume":"67","author":"Hingorani","year":"1998","journal-title":"Exp. Eye Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.preteyeres.2005.09.002","article-title":"Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis","volume":"25","author":"Kumagai","year":"2006","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_31","first-page":"862","article-title":"Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease","volume":"16","author":"Castellanos","year":"2010","journal-title":"Mol. Vis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.exer.2004.11.006","article-title":"TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts","volume":"80","author":"Fukagawa","year":"2005","journal-title":"Exp. Eye Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2332\/allergolint.55.121","article-title":"Fibroblasts as local immune modulators in ocular allergic disease","volume":"55","author":"Fukuda","year":"2006","journal-title":"Allergol. Int."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chigbu, D.I., and Labib, B.A. (2021). Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070658"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/ACI.0b013e32830e6af0","article-title":"Giant papillary conjunctivitis","volume":"8","author":"Elhers","year":"2008","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2003-04-1160","article-title":"Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body","volume":"103","author":"Kambe","year":"2004","journal-title":"Blood"},{"key":"ref_37","unstructured":"Parham, P. (2015). IgE-mediated immunity and allergy. The Immune System, Garland Science."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2222.2007.02886.x","article-title":"The mast cell and allergic diseases: Role in pathogenesis and implications for therapy","volume":"38","author":"Brown","year":"2008","journal-title":"Clin. Exp. Allergy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: Armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/978-1-4419-9533-9_1","article-title":"Mast cell biology: Introduction and overview","volume":"716","author":"Gilfillan","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2174\/138955710793564124","article-title":"Histamine H4 receptor: A novel therapeutic target for immune and allergic responses","volume":"10","author":"Bhatt","year":"2010","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/138955711794519519","article-title":"Histamine H(4) receptor: A novel target for inflammation therapy","volume":"11","author":"Saravanan","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1590\/S0365-05962010000200010","article-title":"Histamine, histamine receptors and antihistamines: New concepts","volume":"85","author":"Criado","year":"2010","journal-title":"An. Bras. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1021\/cr900166w","article-title":"Targeting the histamine H4 receptor","volume":"111","author":"Marson","year":"2011","journal-title":"Chem. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5114\/aoms.2012.27295","article-title":"T lymphocytes as a target of histamine action","volume":"8","author":"Kmiecik","year":"2012","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","article-title":"The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets","volume":"9","author":"Thangam","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_47","first-page":"172","article-title":"The ocular surface: From physiology to the ocular allergic diseases","volume":"60","author":"Santacruz","year":"2013","journal-title":"Rev. Alerg. Mex."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1167\/iovs.11-8748","article-title":"Role of histamine and its receptor subtypes in stimulation of conjunctival goblet cell secretion","volume":"53","author":"Hayashi","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.4049\/jimmunol.179.11.7907","article-title":"Functional expression of H4 histamine receptor in human natural killer cells, monocytes, and dendritic cells","volume":"179","author":"Damaj","year":"2007","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molimm.2014.05.007","article-title":"Functional characterization of histamine H4 receptor on human mast cells","volume":"62","author":"Jemima","year":"2014","journal-title":"Mol. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/sj.bjp.0705530","article-title":"Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor","volume":"140","author":"Buckland","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1034\/j.1600-0420.2000.078s230018.x","article-title":"Role of histamine in allergic conjunctivitis","volume":"78","author":"Leonardi","year":"2000","journal-title":"Acta Ophthalmol. Scand. Suppl."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaci.2015.08.047","article-title":"A histamine-independent itch pathway is required for allergic ocular itch","volume":"137","author":"Huang","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Reinach, P.S., Mergler, S., Okada, Y., and Saika, S. (2015). Ocular transient receptor potential channel function in health and disease. BMC Ophthalmol., 15.","DOI":"10.1186\/s12886-015-0135-7"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1083\/jcb.107.1.321","article-title":"Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells","volume":"107","author":"Dustin","year":"1988","journal-title":"J. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3389\/fimmu.2018.00952","article-title":"LFA-1 in T Cell Migration and Differentiation","volume":"9","author":"Walling","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1182\/blood-2005-09-3695","article-title":"Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response","volume":"107","author":"Evans","year":"2006","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12026-009-8101-1","article-title":"Leukocyte integrins and their ligand interactions","volume":"45","author":"Hyun","year":"2009","journal-title":"Immunol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0092-8674(87)90104-8","article-title":"Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1)","volume":"51","author":"Marlin","year":"1987","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ceb.2017.01.003","article-title":"Focal adhesion kinase signaling in unexpected places","volume":"45","author":"Kleinschmidt","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.alit.2014.09.001","article-title":"The role of leukotrienes in allergic diseases","volume":"64","author":"Liu","year":"2015","journal-title":"Allergol. Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0014-2999(87)90359-1","article-title":"The role of leukotriene D4 as a mediator of allergic conjunctivitis in the guinea-pig","volume":"134","author":"Garceau","year":"1987","journal-title":"Eur. J. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jaip.2012.07.001","article-title":"Leukotriene receptor antagonists in allergic eye disease: A systematic review and meta-analysis","volume":"1","author":"Gane","year":"2013","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yamanishi, R., Okada, N., Shimizu, E., and Fujishima, H. (2021). Elevated levels of prostaglandin E2 in the tears of patients with severe allergic conjunctivitis and primary cultured conjunctival cells are suppressed by ketotifen and dexamethasone. BMJ Open Ophthalmol., 6.","DOI":"10.1136\/bmjophth-2020-000571"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lee, K., Lee, S.H., and Kim, T.H. (2020). The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051851"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int. Anesthesiol. Clin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2222.2006.02499.x","article-title":"Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures","volume":"36","author":"Leonardi","year":"2006","journal-title":"Clin. Exp. Allergy"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/S0092-8674(02)00701-8","article-title":"Cytokine signaling in 2002: New surprises in the Jak\/Stat pathway","volume":"109","author":"Gadina","year":"2002","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun. Signal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"Murray","year":"2008","journal-title":"Immunity"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1067\/mai.2000.106899","article-title":"Cytokine receptor signaling pathways","volume":"105","author":"Leonard","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/imm.13200","article-title":"Understanding the mechanisms that facilitate specificity, not redundancy, of chemokine-mediated leukocyte recruitment","volume":"160","author":"Dyer","year":"2020","journal-title":"Immunology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.4049\/jimmunol.0904177","article-title":"The role of the CCL2\/CCR2 axis in mouse mast cell migration in vitro and in vivo","volume":"184","author":"Collington","year":"2010","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.176.3.781","article-title":"Macrophage inflammatory protein-1 alpha activates basophils and mast cells","volume":"176","author":"Alam","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/ACI.0000000000000676","article-title":"Chemokines in allergic conjunctivitis","volume":"20","author":"Erdinest","year":"2020","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9440(10)64177-6","article-title":"Eosinophil recruitment in type-2 hypersensitivity pulmonary granulomas: Source and contribution of monocyte chemotactic protein-3 (CCL7)","volume":"161","author":"Shang","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4049\/jimmunol.1502416","article-title":"Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis","volume":"198","author":"Kuo","year":"2017","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ACI.0b013e3282ef8674","article-title":"Immunopathogenesis of ocular allergy: A schematic approach to different clinical entities","volume":"7","author":"Leonardi","year":"2007","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.33590\/emj\/10312711","article-title":"Immunopathology of allergic conjunctivitis","volume":"3","author":"Chigbu","year":"2018","journal-title":"Eur. Med. J."},{"key":"ref_81","first-page":"620","article-title":"Mast Cell: A Multi-Functional Master Cell","volume":"6","author":"Dileepan","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/blood-2004-06-2091","article-title":"Phospholipase D1 regulates high-affinity IgE receptor-induced mast cell degranulation","volume":"104","author":"Hitomi","year":"2004","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11882-010-0163-6","article-title":"New developments in the use of histamine and histamine receptors","volume":"11","author":"Smuda","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.4049\/jimmunol.179.6.3425","article-title":"Histamine improves antigen uptake and cross-presentation by dendritic cells","volume":"179","author":"Amaral","year":"2007","journal-title":"J. Immunol."},{"key":"ref_85","first-page":"94","article-title":"Consensus document on allergic conjunctivitis (DECA)","volume":"25","author":"Montero","year":"2015","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.anai.2012.02.015","article-title":"Environmental assessment and exposure control: A practice parameter--furry animals","volume":"108","author":"Portnoy","year":"2012","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13223-020-0403-9","article-title":"A contemporary look at allergic conjunctivitis","volume":"16","author":"Dupuis","year":"2020","journal-title":"Allergy Asthma Clin. Immunol. Off. J. Can. Soc. Allergy Clin. Immunol."},{"key":"ref_88","first-page":"451","article-title":"Topical treatments for seasonal allergic conjunctivitis: Systematic review and meta-analysis of efficacy and effectiveness","volume":"54","author":"Owen","year":"2004","journal-title":"Br. J. Gen. Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jama.2013.280318","article-title":"Conjunctivitis: A systematic review of diagnosis and treatment","volume":"310","author":"Azari","year":"2013","journal-title":"JAMA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/all.12986","article-title":"Conjunctival allergen provocation test: Guidelines for daily practice","volume":"72","author":"Fauquert","year":"2017","journal-title":"Allergy"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/all.12009","article-title":"Ocular allergy: Recognizing and diagnosing hypersensitivity disorders of the ocular surface","volume":"67","author":"Leonardi","year":"2012","journal-title":"Allergy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/ACI.0b013e328364ec3a","article-title":"Allergic conjunctivitis: An update on diagnosis and management","volume":"13","year":"2013","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1990.01070060068051","article-title":"Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis","volume":"108","author":"Abelson","year":"1990","journal-title":"Arch. Ophthalmol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/aap.2007.28.2955","article-title":"Montelukast in allergic diseases beyond asthma","volume":"28","author":"Leonardi","year":"2007","journal-title":"Allergy Asthma Proc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clae.2009.08.002","article-title":"The management of allergic eye diseases in primary eye care","volume":"32","author":"Chigbu","year":"2009","journal-title":"Cont. Lens. Anterior Eye"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/978-1-4615-0717-8_149","article-title":"Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect","volume":"506","author":"Welch","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11882-019-0844-8","article-title":"Emerging Therapeutics for Ocular Surface Disease","volume":"19","author":"Bielory","year":"2019","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Gomes, P.J., Ciolino, J.B., Arranz, P., Hernandez, G., and Fernandez, N. (2022). Efficacy of once-daily ophthalmic bilastine for the treatment of allergic conjunctivitis: A dose-finding study. J. Investig. Allergol. Clin. Immunol.","DOI":"10.18176\/jiaci.0800"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2165\/00003495-199550060-00009","article-title":"Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis","volume":"50","author":"Noble","year":"1995","journal-title":"Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.iac.2007.12.011","article-title":"Ocular allergy overview","volume":"28","author":"Bielory","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0149-2918(02)85042-1","article-title":"Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model","volume":"24","author":"Leonardi","year":"2002","journal-title":"Clin. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bph.12138","article-title":"Twenty-first century mast cell stabilizers","volume":"170","author":"Finn","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/CRIAI:20:2:201","article-title":"Ocular allergy treatments","volume":"20","author":"Bielory","year":"2001","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2165\/00003495-200262110-00004","article-title":"Ocular allergy guidelines: A practical treatment algorithm","volume":"62","author":"Bielory","year":"2002","journal-title":"Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2222.1999.00501.x","article-title":"Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis","volume":"29","author":"Verin","year":"1999","journal-title":"Clin. Exp. Allergy"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF02853155","article-title":"Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis","volume":"17","author":"Alexander","year":"2000","journal-title":"Adv. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/187221311794474883","article-title":"Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis","volume":"5","author":"Mishra","year":"2011","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1034\/j.1398-9995.2003.00081.x","article-title":"Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: Consequences for allergic eye diseases","volume":"58","author":"Woerly","year":"2003","journal-title":"Allergy"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2500\/108854191778879313","article-title":"The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis","volume":"12","author":"Nabe","year":"1991","journal-title":"Allergy Proc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1185\/030079903125001794","article-title":"Topical azelastine in perennial allergic conjunctivitis","volume":"19","author":"Canonica","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003495-200565020-00004","article-title":"Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis","volume":"65","author":"Bielory","year":"2005","journal-title":"Drugs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/S0149-2918(03)80315-6","article-title":"Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans","volume":"25","author":"Leonardi","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1081-1206(10)61155-6","article-title":"Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy","volume":"95","author":"Berger","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0149-2918(03)80115-7","article-title":"A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis","volume":"25","author":"Abelson","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0149-2918(03)80205-9","article-title":"One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears","volume":"25","author":"Abelson","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/bjo.87.10.1206","article-title":"Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis","volume":"87","author":"Kidd","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.clinthera.2005.09.013","article-title":"Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: A 30-day, randomized, double-masked, artificial tear substitute-controlled trial","volume":"27","author":"Avunduk","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Castillo, M., Scott, N.W., Mustafa, M.Z., Mustafa, M.S., and Azuara-Blanco, A. (2015). Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst. Rev., CD009566.","DOI":"10.1002\/14651858.CD009566.pub2"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/09273948.2016.1158282","article-title":"Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis","volume":"25","author":"Kam","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.clinthera.2009.09.001","article-title":"Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children","volume":"31","author":"Abelson","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2010.02.007","article-title":"Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis","volume":"150","author":"Macejko","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/OPTH.S35431","article-title":"Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference","volume":"6","author":"McCabe","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_123","first-page":"149","article-title":"Updates in the treatment of ocular allergies","volume":"3","author":"Kari","year":"2010","journal-title":"J. Asthma Allergy"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2019.02028","article-title":"More than Suppression: Glucocorticoid Action on Monocytes and Macrophages","volume":"10","author":"Ehrchen","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"789623","DOI":"10.1155\/2012\/789623","article-title":"Advances in corticosteroid therapy for ocular inflammation: Loteprednol etabonate","volume":"2012","author":"Comstock","year":"2012","journal-title":"Int. J. Inflamm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0091-6749(99)70107-7","article-title":"Apoptosis of eosinophils and lymphocytes in allergic inflammation","volume":"104","author":"Ohta","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1043-6618(05)80058-1","article-title":"Lipocortin and vasocortin: Two species of anti-inflammatory proteins mimicking the effects of glucocorticoids","volume":"25","author":"Sautebin","year":"1992","journal-title":"Pharmacol. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2332\/allergolint.55.279","article-title":"Dexamethasone suppresses histamine synthesis by repressing both transcription and activity of HDC in allergic rats","volume":"55","author":"Kitamura","year":"2006","journal-title":"Allergol. Int."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.ICL.0000092071.82938.46","article-title":"Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis","volume":"30","author":"Ilyas","year":"2004","journal-title":"Eye Contact Lens."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0161-6420(99)90077-5","article-title":"A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis","volume":"106","author":"Shulman","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0091-6749(98)70094-6","article-title":"A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis","volume":"102","author":"Dell","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1034\/j.1600-0420.2003.00079.x","article-title":"Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis","volume":"81","author":"Yaylali","year":"2003","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2500\/aap.2009.30.3238","article-title":"Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents","volume":"30","author":"Anolik","year":"2009","journal-title":"Allergy Asthma Proc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2500\/aap.2009.30.3204","article-title":"Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy","volume":"30","author":"Andrews","year":"2009","journal-title":"Allergy Asthma Proc."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11882-010-0087-1","article-title":"Allergic conjunctivitis and the impact of allergic rhinitis","volume":"10","author":"Bielory","year":"2010","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.survophthal.2018.12.001","article-title":"Vernal Keratoconjunctivitis","volume":"64","author":"Singhal","year":"2019","journal-title":"Surv. Ophthalmol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"396987","DOI":"10.1155\/2014\/396987","article-title":"Retrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chinese","volume":"2014","author":"Wu","year":"2014","journal-title":"Sci. World J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.4103\/0976-9668.166051","article-title":"Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis","volume":"6","author":"Hazarika","year":"2015","journal-title":"J. Nat. Sci. Biol. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev.med.60.041807.123524","article-title":"Immunomodulation of allergic disease","volume":"60","author":"Broide","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1398-9995.1995.tb01170.x","article-title":"Grass pollen immunotherapy: Efficacy and safety during a 4-year follow-up study","volume":"50","author":"Walker","year":"1995","journal-title":"Allergy"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1398-9995.1984.tb00865.x","article-title":"Blood lymphocyte proliferation response to pollen extract as a monitor of immunotherapy","volume":"39","author":"Moller","year":"1984","journal-title":"Allergy"},{"key":"ref_143","first-page":"745","article-title":"Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy","volume":"8","author":"Baiula","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/1871528113666141106101356","article-title":"Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis","volume":"13","author":"Baiula","year":"2014","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_145","first-page":"3208","article-title":"Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist","volume":"17","author":"Baiula","year":"2011","journal-title":"Mol. Vis."},{"key":"ref_146","first-page":"1515","article-title":"Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells","volume":"19","author":"Cavet","year":"2013","journal-title":"Mol. Vis."},{"key":"ref_147","first-page":"1791","article-title":"Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells","volume":"16","author":"Cavet","year":"2010","journal-title":"Mol. Vis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1476-5381.2009.00238.x","article-title":"Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases","volume":"158","author":"Schacke","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1167\/iovs.10-5598","article-title":"In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease","volume":"52","author":"Shafiee","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1167\/iovs.09-4202","article-title":"Reduced myocilin expression in cultured monkey trabecular meshwork cells induced by a selective glucocorticoid receptor agonist: Comparison with steroids","volume":"51","author":"Pfeffer","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.coph.2010.04.007","article-title":"Targeting inflammation using selective glucocorticoid receptor modulators","volume":"10","author":"Haegeman","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1167\/iovs.08-2154","article-title":"Transcriptional analyses before and after suppression of immediate hypersensitivity reactions by CCR3 blockade in eyes with experimental allergic conjunctivitis","volume":"49","author":"Komatsu","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"16418","DOI":"10.1073\/pnas.0607863103","article-title":"A central regulatory role for eosinophils and the eotaxin\/CCR3 axis in chronic experimental allergic airway inflammation","volume":"103","author":"Fulkerson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.immunol.18.1.347","article-title":"Molecular genetics of allergic diseases","volume":"18","author":"Ono","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00130832-200410000-00018","article-title":"Tear cytokines in acute and chronic ocular allergic inflammation","volume":"4","author":"Cook","year":"2004","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3109\/02770903.2010.527025","article-title":"Immunochromatographic assay for measurement of total IgE in tears, nasal mucus, and saliva of patients with allergic rhinoconjunctivitis","volume":"47","author":"Mimura","year":"2010","journal-title":"J. Asthma"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1111\/j.1755-3768.2010.01978.x","article-title":"Cytokine and chemokine levels in tears from healthy subjects","volume":"88","author":"Carreno","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/02713680802190085","article-title":"Multiple cytokine analysis in human tears: An optimized procedure for cytometric bead-based assay","volume":"33","author":"LaFrance","year":"2008","journal-title":"Curr. Eye Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/bjo.84.12.1360","article-title":"Chemokines in the limbal form of vernal keratoconjunctivitis","volume":"84","author":"Struyf","year":"2000","journal-title":"Br. J. Ophthalmol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00417-014-2683-6","article-title":"Total IgE and eotaxin (CCL11) contents in tears of patients suffering from seasonal allergic conjunctivitis","volume":"252","author":"Eperon","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood.V83.1.72.72","article-title":"Effects of stem cell factor (kit-ligand) and interleukin-3 on the growth and serine proteinase expression of rat bone-marrow-derived or serosal mast cells","volume":"83","author":"Haig","year":"1994","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1167\/iovs.09-3637","article-title":"Blocking mast cell-mediated type I hypersensitivity in experimental allergic conjunctivitis by monocyte chemoattractant protein-1\/CCR2","volume":"50","author":"Tominaga","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ICL.0000000000000276","article-title":"Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease","volume":"43","author":"Goldstein","year":"2017","journal-title":"Eye Contact Lens."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","article-title":"Topical interleukin 1 receptor antagonist for treatment of dry eye disease: A randomized clinical trial","volume":"131","author":"Amparo","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"ref_165","first-page":"3041","article-title":"Prevention of allergic eye disease by treatment with IL-1 receptor antagonist","volume":"40","author":"Miyazaki","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1096\/fj.13-229948","article-title":"TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis","volume":"27","author":"Liu","year":"2013","journal-title":"FASEB J."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1523\/JNEUROSCI.4643-06.2007","article-title":"TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase","volume":"27","author":"Shim","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/09273948.2016.1231330","article-title":"TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model","volume":"26","author":"Kwon","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"106737","DOI":"10.1016\/j.intimp.2020.106737","article-title":"Tofacitinib suppresses mast cell degranulation and attenuates experimental allergic conjunctivitis","volume":"86","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1089\/jop.2020.0056","article-title":"Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement","volume":"36","author":"Mandell","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/jop.2020.0087","article-title":"A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease","volume":"37","author":"Clark","year":"2021","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/BJ20111752","article-title":"Cell signalling by reactive lipid species: New concepts and molecular mechanisms","volume":"442","author":"Higdon","year":"2012","journal-title":"Biochem. J."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.exer.2007.09.010","article-title":"Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells","volume":"86","author":"Kalariya","year":"2008","journal-title":"Exp. Eye Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.imlet.2012.05.005","article-title":"Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells\u2014Implications for age-related macular degeneration (AMD)","volume":"147","author":"Kauppinen","year":"2012","journal-title":"Immunol. Lett."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-017-0517-x","article-title":"Malondialdehyde-acetaldehyde (MAA) adducted surfactant protein induced lung inflammation is mediated through scavenger receptor a (SR-A1)","volume":"18","author":"Sapkota","year":"2017","journal-title":"Respir. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OPTH.S345324","article-title":"Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure","volume":"16","author":"Clark","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ajo.2021.04.023","article-title":"Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial","volume":"230","author":"Clark","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Katoh, K. (2020). FAK-Dependent Cell Motility and Cell Elongation. Cells, 9.","DOI":"10.3390\/cells9010192"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"C1339","DOI":"10.1152\/ajpcell.00144.2006","article-title":"Focal adhesion kinase mediates cell survival via NF-kappaB and ERK signaling pathways","volume":"292","author":"Huang","year":"2007","journal-title":"Am. J. Physiology. Cell Physiol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"16309","DOI":"10.1074\/jbc.275.21.16309","article-title":"Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60","volume":"275","author":"Sonoda","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S1357-2725(97)00051-4","article-title":"Role of focal adhesion kinase in integrin signaling","volume":"29","author":"Guan","year":"1997","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"17788","DOI":"10.1074\/jbc.M100984200","article-title":"Src family kinases are required for integrin-mediated but not for G protein-coupled receptor stimulation of focal adhesion kinase autophosphorylation at Tyr-397","volume":"276","author":"Salazar","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"114722","DOI":"10.1016\/j.bcp.2021.114722","article-title":"FAK inhibitor PF-431396 suppresses IgE-mediated mast cell activation and allergic inflammation in mice","volume":"192","author":"Chen","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol. Int."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10792-021-02010-w","article-title":"Effects of omalizumab on allergic conjunctivitis","volume":"42","author":"Kirikkaya","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Taille, C., Doan, S., Neukirch, C., and Aubier, M. (2010). Omalizumab for severe atopic keratoconjunctivitis. BMJ Case Rep., 2010.","DOI":"10.1136\/bcr.04.2010.2919"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","article-title":"Omalizumab Treatment of Vernal Keratoconjunctivitis","volume":"134","author":"Heffler","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaapos.2012.12.153","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"Sharma","year":"2013","journal-title":"J. AAPOS"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/ICU.0000000000000532","article-title":"Ocular involvement in atopic disease: A review","volume":"29","author":"Patel","year":"2018","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3906\/sag-1212-23","article-title":"Comparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis model","volume":"44","author":"Bozkurt","year":"2014","journal-title":"Turk. J. Med. Sci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/ACI.0000000000000551","article-title":"Dupilumab after the 2017 approval for the treatment of atopic dermatitis: What\u2019s new and what\u2019s next?","volume":"19","author":"Thijs","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: Clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijpharm.2015.12.037","article-title":"Topical delivery of aqueous micellar resolvin E1 analog (RX-10045)","volume":"498","author":"Cholkar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/JEP.S237487","article-title":"Experimental Pharmacotherapy for Dry Eye Disease: A Review","volume":"13","author":"Baiula","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"774601","DOI":"10.3389\/fimmu.2021.774601","article-title":"Conditioned Medium of Human Amniotic Epithelial Cells Alleviates Experimental Allergic Conjunctivitis Mainly by IL-1ra and IL-10","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","article-title":"Stem Cell Therapies in Clinical Trials: Progress and Challenges","volume":"17","author":"Trounson","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"5432301","DOI":"10.1155\/2019\/5432301","article-title":"Therapeutic Potential of Human Amniotic Epithelial Cells on Injuries and Disorders in the Central Nervous System","volume":"2019","author":"Xu","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.yjmcc.2012.06.020","article-title":"Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis","volume":"53","author":"Ohshima","year":"2012","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/art.37894","article-title":"Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.alit.2019.08.001","article-title":"Mesenchymal stem cells in allergic diseases: Current status","volume":"69","author":"Li","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1042\/CS20160328","article-title":"Serelaxin improves the therapeutic efficacy of RXFP1-expressing human amnion epithelial cells in experimental allergic airway disease","volume":"130","author":"Royce","year":"2016","journal-title":"Clin. Sci."},{"key":"ref_210","first-page":"S193","article-title":"Comparison of MSC properties in two different hydrogels. Impact of mechanical properties","volume":"28","author":"Yu","year":"2017","journal-title":"Biomed. Mater. Eng."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00403-019-01967-0","article-title":"Effects of combination of mizolastine and proteoglycan on chronic urticaria: A randomized controlled trial","volume":"311","author":"Xiong","year":"2019","journal-title":"Arch. Dermatol. Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.2147\/IJN.S335482","article-title":"Formulation and Pathohistological Study of Mizolastine-Solid Lipid Nanoparticles-Loaded Ocular Hydrogels","volume":"16","author":"Girgis","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/108076804773710812","article-title":"A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis","volume":"20","author":"Gous","year":"2004","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02850117","article-title":"Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: A comparative study","volume":"20","author":"Shulman","year":"2003","journal-title":"Adv. Ther."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/10807680260362759","article-title":"Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: A pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies","volume":"18","author":"Abelson","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1248\/bpb.28.473","article-title":"Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats","volume":"28","author":"Minami","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0169-409X(97)00121-X","article-title":"Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery","volume":"31","author":"Ron","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.2147\/DDDT.S308448","article-title":"In vivo and in vitro Evaluation of in situ Gel Formulation of Pemirolast Potassium in Allergic Conjunctivitis","volume":"15","author":"Shen","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/ICO.0000000000001911","article-title":"Management of Ocular Allergy Itch With an Antihistamine-Releasing Contact Lens","volume":"38","author":"Pall","year":"2019","journal-title":"Cornea"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.xphs.2020.01.022","article-title":"Novel Polyvinyl Pyrrolidone-Loaded Olopatadine HCl-Laden Doughnut Contact Lens to Treat Allergic Conjunctivitis","volume":"109","author":"Xue","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Minami, T., Ishida, W., Kishimoto, T., Nakajima, I., Hino, S., Arai, R., Matsunaga, T., Fukushima, A., and Yamagami, S. (2019). In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210362"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ajo.2021.03.017","article-title":"Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis","volume":"229","author":"McLaurin","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1167\/iovs.17-23066","article-title":"A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model","volume":"59","author":"Liu","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","article-title":"A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study","volume":"126","author":"Leonardi","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.mehy.2013.08.007","article-title":"Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis","volume":"81","author":"Garg","year":"2013","journal-title":"Med. Hypotheses"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Liu, Y.C., Lin, M.T., Ng, A.H.C., Wong, T.T., and Mehta, J.S. (2020). Nanotechnology for the Treatment of Allergic Conjunctival Diseases. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110351"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/547\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:03:23Z","timestamp":1760137403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":226,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ph15050547"],"URL":"https:\/\/doi.org\/10.3390\/ph15050547","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]}}}